Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Operating Leases (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Operating Leases for 6 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 223.04% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, up 223.04%, and an annual FY2025 reading of $1.9 million, up 223.04% over the prior year.
  • Operating Leases was $1.9 million for Q4 2025 at SAB Biotherapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $2.5 million in Q1 2025 and bottomed at $227652.0 in Q1 2023.
  • Average Operating Leases over 5 years is $1.1 million, with a median of $772605.0 recorded in 2022.
  • The sharpest move saw Operating Leases tumbled 83.25% in 2023, then soared 344.91% in 2025.
  • Year by year, Operating Leases stood at $1.7 million in 2021, then crashed by 78.15% to $361225.0 in 2022, then soared by 76.01% to $635777.0 in 2023, then decreased by 8.59% to $581148.0 in 2024, then soared by 223.04% to $1.9 million in 2025.
  • Business Quant data shows Operating Leases for SABS at $1.9 million in Q4 2025, $2.0 million in Q3 2025, and $2.3 million in Q2 2025.